Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Large Increase in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily volume of 92,500 shares, the short-interest ratio is presently 2.3 days.

Analyst Ratings Changes

A number of research firms recently weighed in on COYA. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Wednesday, December 18th. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Down 3.9 %

COYA traded down $0.22 during midday trading on Friday, reaching $5.38. 63,988 shares of the company’s stock were exchanged, compared to its average volume of 51,707. Coya Therapeutics has a one year low of $4.75 and a one year high of $10.69. The firm has a market capitalization of $89.88 million, a price-to-earnings ratio of -8.28 and a beta of 0.46. The business has a 50-day simple moving average of $6.02 and a two-hundred day simple moving average of $6.49.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Arun Swaminathan purchased 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the transaction, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at approximately $36,700. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders acquired 9,510 shares of company stock valued at $69,615. Insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in COYA. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics in the second quarter valued at $101,000. GHP Investment Advisors Inc. bought a new position in shares of Coya Therapeutics in the third quarter worth about $169,000. Finally, Geode Capital Management LLC raised its stake in shares of Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.